Lack of immunomodulatory interleukin-27 enhances oncogenic properties of mutant p53 in vivo

Clinical Cancer Research

Volumn 22, Issue 15, 2016, Pages 3876-3883

  Dibra, Denada ^a   Mitra, Abhisek ^a   Newman, Melisa ^b   Xia, Xueqing ^a   Cutrera, Jeffry J ^a   Gagea, Mihai ^a   Kleinerman, Eugenie S ^a   Lozano, Guillermina ^a   Li, Shulin ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Banfield Pet Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 27; MUTANT PROTEIN; PROTEIN P53; IL27RA PROTEIN, HUMAN; INTERLEUKIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; HETEROZYGOTE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; ANIMAL; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE MODEL; GENETICS; GENOTYPE; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; MUTATION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENOTYPE; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INTERLEUKIN-27; MICE; MICE, KNOCKOUT; MUTATION; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; X-RAY MICROTOMOGRAPHY;

EID: 84980011834     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2052     Document Type: Article

References (23)

1. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008;22:1337-44.
2. Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, et al. Multiple stress signals activate mutant p53 in vivo. Cancer Res 2011;71:7168-75.
3. Villarino AV, Stumhofer JS, Saris CJ, Kastelein RA, de Sauvage FJ, Hunter CA. IL-27 limits IL-2 production during Th1 differentiation. J Immunol 2006;176:237-47.
4. Lucas S, Ghilardi N, Li J, de Sauvage FJ. IL-27 regulates IL-12 responsiveness of naive CD4(+) T cells through Stat1-dependent and -independent mechanisms. Proc Natl Acad Sci U S A 2003;100:15047-52.
5. Diveu C, McGeachy MJ, Boniface K, Stumhofer JS, Sathe M, Joyce-Shaikh B, et al. IL-27 Blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol 2009;182:5748-56.
6. Awasthi A, Carrier Y, Peron JPS, Bettelli E, Kamanaka M, Flavell RA, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 2007;8:1380-9.
7. Fitzgerald DC, Zhang GX, El-Behi M, Fonseca-Kelly Z, Li H, Yu S, et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007;8:1372-9.
8. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007;8:1363-71.
9. Chiyo M, Shimozato O, Yu L, Kawamura K, Iizasa T, Fujisawa T, et al. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer 2005;115:437-42.
10. Dibra D, Cutrera JJ, Xia X, Birkenbach MP, Li S. Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance. Cancer Res 2009;69:5505-13.
11. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, et al. Potent antitumor activity of interleukin-27. Cancer Res 2004;64:1152-6.
12. Zorzoli A, Di Carlo E, Cocco C, Ognio E, Ribatti D, Ferretti E, et al. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice. Clin Cancer Res 2012;18: 1630-40.
13. Ho MY, Leu SJ, Sun GH, Tao MH, Tang SJ, Sun KH. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol 2009;183:6217-26.
14. Hirahara K, Ghoreschi K, Yang XP, Takahashi H, Laurence A, Vahedi G, et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 2012;36:1017-30.
15. Bankson JA, Ji L, Ravoori M, Han L, Kundra V. Echo-planar imaging for MRI evaluation of intrathoracic tumors in murine models of lung cancer. J Magn Reson Imaging 2008;27:57-62.
16. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119:861-72.
17. Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, et al. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci U S A 2014;111:11145-50.
18. Dibra D, Cutrera J, Xia X, Kallakury B, Mishra L, Li S. Interleukin-30: a novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury. Hepatology 2012;55: 1204-14.
19. Rountree CB, Ding W, Dang H, Vankirk C, Crooks GM. Isolation of CD133+ liver stem cells for clonal expansion. J Vis Exp 2011 Oct 10;(56). pii: 3183.
20. Cutrera J, Johnson B, Ellis L, Li S. Intraosseous inoculation of tumor cells into bone marrow promotes distant metastatic tumor development: a novel tool for mechanistic and therapeutic studies. Cancer Lett 2013; 329:68-73.
21. Natividad KD, Junankar SR, Mohd Redzwan N, Nair R, Wirasinha RC, King C, et al. Interleukin-27 signaling promotes immunity against endogenously arising murine tumors. PLoS One 2013;8:e57469.
22. Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, et al. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res 2011;31:2283-90.
23. Tang YJ, Wang JL, Nong LG, Lan CG, Zha ZG, Liao PH. Associations of IL-27 polymorphisms and serum IL-27p28 levels with osteosarcoma risk. Medicine 2014;93:e56.